EyeGene Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 66
Employees
  • Stock Symbol
  • 185490
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $20.87
  • (As of Tuesday Closing)

EyeGene General Information

Description

EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Healthcare Technology Systems
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
  • Gangseo-gu, Seoul 401
  • B-dong 910 Gayang-dong
  • Seoul, Gangseo-gu
  • South Korea
+82 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EyeGene Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$20.87 $19.56 $6.63 - $51.88 $413M 19.8M 823K -$0.58

EyeGene Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 601,374 122,190 96,166 117,177
Revenue 2,958 2,849 3,641 1,852
EBITDA (7,318) (10,445) (5,745) (5,803)
Net Income (7,767) (12,588) (7,496) (5,375)
Total Assets 120,987 40,724 40,842 48,327
Total Debt 9,756 14,250 13,537 11,637
Public Fundamental Data provided by Morningstar, Inc. disclaimer

EyeGene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EyeGene‘s full profile, request access.

Request a free trial

EyeGene Patents

EyeGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3868392-A1 Pharmaceutical composition for preventing or treating inflammatory diseases Pending 19-Oct-2018 000000000
US-20190290749-A1 Immune modulator and vaccine composition containing the same Granted 31-Oct-2016 00000000000
US-10918709-B2 Immune modulator and vaccine composition containing the same Active 31-Oct-2016 000000000
US-20190255171-A1 Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same Granted 31-Oct-2016 000000000 0
US-10874733-B2 Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same Active 31-Oct-2016 A61K39/25

EyeGene Executive Team (2)

Name Title Board Seat Contact Info
Wonil Yoo Ph.D Chief Executive Officer
Yangje Cho Ph.D Chief Technology Officer
To view EyeGene’s complete executive team members history, request access »

EyeGene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyeGene Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore EyeGene‘s full profile, request access.

Request a free trial

EyeGene Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000000 31-Jan-2020 00000 00000 00 00.000 Drug Discovery
To view EyeGene’s complete investments history, request access »